The long term prognostic significance of c-erbB-2 in primary breast cancer
- PMID: 1672256
- PMCID: PMC1971845
- DOI: 10.1038/bjc.1991.103
The long term prognostic significance of c-erbB-2 in primary breast cancer
Abstract
The expression of the c-erbB-2 oncogene has been evaluated using an immunohistochemical technique with the 21N polyclonal antibody in paraffin embedded tissue from 465 patients treated between the years 1975-1981 for Stage I and II breast cancer. One hundred and four (22%) patients exhibited positive staining. This was not associated with any other variables. Expression of the oncogene was associated with significantly poorer survival which was independent of other tumour variables.
Similar articles
-
Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.Cancer Res. 1991 Jun 15;51(12):3296-303. Cancer Res. 1991. PMID: 1674898
-
c-erbB-2 oncoprotein expression in primary and advanced breast cancer.Br J Cancer. 1991 Mar;63(3):439-43. doi: 10.1038/bjc.1991.101. Br J Cancer. 1991. PMID: 1672254 Free PMC article.
-
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.Cancer Res. 1991 Jan 15;51(2):556-67. Cancer Res. 1991. PMID: 1670762
-
Neu (C-erbB-2) oncogene in breast cancer and its possible association with the risk of distant metastases. A retrospective study and review of literature.Acta Oncol. 1990;29(7):931-4. doi: 10.3109/02841869009096392. Acta Oncol. 1990. PMID: 1979748 Review.
-
c-erbB-2 oncogene as a prognostic marker in breast cancer.Br J Cancer. 1991 Mar;63(3):328-32. doi: 10.1038/bjc.1991.78. Br J Cancer. 1991. PMID: 1672251 Free PMC article. Review. No abstract available.
Cited by
-
Biological indices in the assessment of breast cancer.Clin Mol Pathol. 1995 Oct;48(5):M221-38. doi: 10.1136/mp.48.5.m221. Clin Mol Pathol. 1995. PMID: 16696013 Free PMC article. No abstract available.
-
Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index.Support Care Cancer. 2010 Dec;18(12):1553-64. doi: 10.1007/s00520-009-0778-0. Epub 2009 Nov 11. Support Care Cancer. 2010. PMID: 19904562
-
c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.Br J Cancer. 1997;75(11):1667-73. doi: 10.1038/bjc.1997.283. Br J Cancer. 1997. PMID: 9184184 Free PMC article.
-
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.Breast Cancer Res Treat. 2020 Aug;182(3):613-622. doi: 10.1007/s10549-020-05709-z. Epub 2020 Jun 5. Breast Cancer Res Treat. 2020. PMID: 32504284 Free PMC article. Clinical Trial.
-
Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer.Med Oncol. 2009;26(3):335-43. doi: 10.1007/s12032-008-9126-3. Epub 2008 Nov 12. Med Oncol. 2009. PMID: 19003545
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous